What Does Clearance Mean? Knowledge Base What Does Clearance Mean? Drug clearance is an extremely important topic in the science of pharmacokinetics. Drug clearance defines…CertaraJune 13, 2010
Understanding Volume of Distribution BlogKnowledge Base Understanding Volume of Distribution Watch our on demand webinar to discover fast, flexible, frictionless PK/PD workflows with Phoenix Cloud.…CertaraJune 5, 2010
Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation Publication Selection of Alternative CYP3A4 Probe Substrates for Clinical Drug Interaction Studies Using In Vitro Data and In Vivo Simulation Understanding the potential for cytochrome P450-mediated drug-drug interactions (DDIs) is a critical step in the drug discovery process. DDIs…CertaraJune 1, 2010
Concentration–Effect Relationships for the Drug of Abuse—γ-hydroxybutyric Acid Publication Concentration–Effect Relationships for the Drug of Abuse—γ-hydroxybutyric Acid γ-Hydroxybutyric acid (GHB) is an endogenous neurotransmitter that is abused because of its sedative/hypnotic and…CertaraJune 1, 2010
Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis Publication Pharmacology and Safety of Glycerol Phenylbutyrate in Healthy Adults and Adults with Cirrhosis Phenylbutyric acid (PBA), which is approved for treatment of urea cycle disorders (UCDs) as sodium…CertaraJune 1, 2010
What is Pharmacodynamics? Knowledge Base What is Pharmacodynamics? Starting with definitions is always helpful… so after defining pharmacokinetics, a definition for pharmacodynamics is…CertaraMay 24, 2010
What is Pharmacokinetics? Knowledge Base What is Pharmacokinetics? You might think this is a simple question, especially for an expert in pharmacokinetics. Well,…CertaraMay 16, 2010
Population Pharmacokinetic/Pharmacodynamic Model for a C.E.R.A. in Both ESA-naive and ESA-treated Chronic Kidney Disease Patients with Renal Anemia Publication Population Pharmacokinetic/Pharmacodynamic Model for a C.E.R.A. in Both ESA-naive and ESA-treated Chronic Kidney Disease Patients with Renal Anemia This study aimed to develop a population pharmacokinetic/pharmacodynamic (PK/PD) model for C.E.R.A., a continuous erythropoietin…CertaraMay 1, 2010
Physiologically-based Mechanistic Modeling to Predict Complex Drug–drug Interactions Involving Simultaneous Competitive and Time-dependent Enzyme Inhibition by Parent Compound and Its Metabolite in Both Liver and Gut—The Effect of Diltiazem on the Time-course of Exposure to Triazolam Publication Physiologically-based Mechanistic Modeling to Predict Complex Drug–drug Interactions Involving Simultaneous Competitive and Time-dependent Enzyme Inhibition by Parent Compound and Its Metabolite in Both Liver and Gut—The Effect of Diltiazem on the Time-course of Exposure to Triazolam The aim of this study was to predict the magnitude of metabolic drug-drug interaction (mDDI)…CertaraMarch 18, 2010
Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-based Simulator Publication Identification of Cytochrome P450 Isoforms Involved in the Metabolism of Paroxetine and Estimation of Their Importance for Human Paroxetine Metabolism Using a Population-based Simulator We identify here for the first time the low-affinity cytochrome P450 (P450) isoforms that metabolize…CertaraMarch 1, 2010